What is HC Wainwright’s Forecast for BTAI Q1 Earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities researchers at HC Wainwright issued their Q1 2027 EPS estimates for shares of BioXcel Therapeutics in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.26) EPS and Q4 2027 earnings at ($0.26) EPS.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.58) earnings per share for the quarter, hitting the consensus estimate of ($0.58). The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.15 million.

Several other analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Rodman & Renshaw began coverage on BioXcel Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price on the stock. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Finally, Wall Street Zen cut BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, BioXcel Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $11.00.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $1.18 on Friday. The stock has a 50 day moving average of $1.54 and a 200-day moving average of $1.90. The firm has a market capitalization of $31.95 million, a PE ratio of -0.18 and a beta of 0.30. BioXcel Therapeutics has a 52 week low of $1.08 and a 52 week high of $8.08.

Hedge Funds Weigh In On BioXcel Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BTAI. Millennium Management LLC grew its holdings in BioXcel Therapeutics by 78.5% in the 4th quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock worth $2,936,000 after buying an additional 807,139 shares in the last quarter. Man Group plc bought a new stake in BioXcel Therapeutics during the 4th quarter valued at $91,000. State Street Corp boosted its position in BioXcel Therapeutics by 19.9% during the 4th quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after acquiring an additional 10,500 shares during the period. Jane Street Group LLC acquired a new position in BioXcel Therapeutics during the 4th quarter worth $204,000. Finally, HRT Financial LP bought a new position in shares of BioXcel Therapeutics in the fourth quarter worth $28,000. 30.68% of the stock is currently owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.